Partner & Co-Lead, Healthcare
Kan Chen, Ph.D. is a partner and co-lead of healthcare at Qiming Venture Partners, leading its biotech practice. His portfolio includes Structure Therapeutics (NASDAQ: GPCR), Abbisko (HKEX:02256), LaNova Medicine (acquired by Sinopharma), Medilink, Candid Tx, Allorion Tx, Glubio, etc. Before joining Qiming in 2016, he served as a senior scientist at JNJ. Before that, he was a group leader at Jiangsu Hengrui Medicine.
Kan earned his Ph.D. in cell biology from a joint program between Cleveland Clinic and Case Western Reserve University in the US and finished his postdoctoral training in Immunology at Brigham and Women’s Hospital. He received his bachelor’s degree in biological sciences from Fudan University.